Ability Pharmaceuticals
PrivateLast Round
Early Funding
Mar 11, 2024
Est. Valuation
$31.43M
Total Funding Raised
$12.95M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ability Pharmaceuticals is a biopharmaceutical company that develops oral targeted anticancer compounds for the treatment of various cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ability Pharmaceuticals Comparables
Compare Ability Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kazia Therapeutics | 79% | |
| Celcuity Inc. | 77% | |
| Adlai Nortye Ltd. | 74% | |
Ability Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Mar 11, 2024 | ||||
| Grant | Nov 21, 2022 | ||||
| Grant | Oct 7, 2022 | ||||
| VC Round | Oct 22, 2020 | ||||
| VC Round | Mar 16, 2020 | ||||
VC Round | Sep 12, 2019 |
Key People
Founding team and executive leadership
Carles Domenech
Executive Chairman And Chief Executive Officer, Executive Chairman And Chief Scientific Officer At Ability Pharmaceuticals, Chief Executive Officer VP Business Development And Licensing
Ability Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Early Funding |
| CDTI Innvierte | Early Funding |
| ACCIÓ - Agency for Business Competitiveness | Seed |
| Inveready | VC Round, Early Funding |
| CTI Life Sciences Fund | Early Funding |
| Founders Fund | Seed |
| Center for Technological Development and Innovation | Early Funding, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 13, 2026
Monthly visitors increased 49% MoM, reaching 1K.
- Mar 11, 2024
$7.65M raised from CTI Life Sciences Fund and Inveready.
Ability Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ability Pharmaceuticals's valuation, stock price, and market status.